Activity of flubendazole against developing stages of Dirofilaria immitis in dogs.
A formulation of flubendazole was studied to determine the activity against developing stages of Dirofilaria immitis in artificially infected pups. Flubendazole suspension was administered subcutaneously at a dose rate of 50 mg/kg of body weight once a day for 1, 3, or 5 consecutive days at various times during the experimental period. The pups were necropsied 6 months after the experimental infection, and the heart and pulmonary arteries were examined for adult worms. Optimal activity was obtained when flubendazole suspension was administered subcutaneously for 5 consecutive days, either 1 or 2 months after infection. The formation of encapsulated deposits, containing white viscous fluid, was observed at the injection sites of all treated pups.
D000818:Animals; D000969:Antinematodal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004183:Dirofilaria immitis / Q000187:drug effects; D004184:Dirofilariasis / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D008297:Male; D008463:Mebendazole / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*
D000969:Antinematodal Agents; D001562:Benzimidazoles; D008463:Mebendazole; C018945:flubendazole